Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 29, 2024

SELL
$6.57 - $18.69 $7,227 - $20,559
-1,100 Reduced 7.42%
13,729 $223,000
Q4 2023

Feb 07, 2024

SELL
$4.88 - $7.42 $1,903 - $2,893
-390 Reduced 2.56%
14,829 $101,000
Q3 2023

Nov 02, 2023

BUY
$4.86 - $7.23 $7,275 - $10,823
1,497 Added 10.91%
15,219 $82,000
Q2 2023

Aug 07, 2023

BUY
$5.68 - $10.34 $15,733 - $28,641
2,770 Added 25.29%
13,722 $93,000
Q1 2023

May 09, 2023

SELL
$2.83 - $5.11 $2,006 - $3,622
-709 Reduced 6.08%
10,952 $54,000
Q4 2022

Feb 09, 2023

BUY
$3.0 - $15.17 $3,810 - $19,265
1,270 Added 12.22%
11,661 $56,000
Q3 2022

Nov 09, 2022

SELL
$13.96 - $19.67 $2,847 - $4,012
-204 Reduced 1.93%
10,391 $150,000
Q2 2022

Aug 10, 2022

BUY
$8.22 - $15.13 $87,090 - $160,302
10,595 New
10,595 $160,000
Q4 2021

Feb 09, 2022

SELL
$15.51 - $29.31 $247,710 - $468,110
-15,971 Closed
0 $0
Q3 2021

Nov 09, 2021

BUY
$27.47 - $37.31 $163,034 - $221,434
5,935 Added 59.14%
15,971 $455,000
Q2 2021

Aug 10, 2021

BUY
$25.45 - $37.64 $29,216 - $43,210
1,148 Added 12.92%
10,036 $339,000
Q1 2021

May 10, 2021

SELL
$29.16 - $51.96 $207,619 - $369,955
-7,120 Reduced 44.48%
8,888 $269,000
Q4 2020

Feb 08, 2021

BUY
$37.86 - $54.26 $291,673 - $418,019
7,704 Added 92.77%
16,008 $792,000
Q3 2020

Nov 06, 2020

SELL
$35.13 - $43.62 $187,769 - $233,148
-5,345 Reduced 39.16%
8,304 $318,000
Q2 2020

Aug 05, 2020

BUY
$23.66 - $49.53 $322,935 - $676,034
13,649 New
13,649 $590,000

Others Institutions Holding YMAB

About Y-mAbs Therapeutics, Inc.


  • Ticker YMAB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,719,500
  • Market Cap $566M
  • Description
  • Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment o...
More about YMAB
Track This Portfolio

Track Principal Financial Group Inc Portfolio

Follow Principal Financial Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Principal Financial Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Principal Financial Group Inc with notifications on news.